This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-estimates-revisions: Archive
Compared to Estimates, Lennar (LEN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Lennar (LEN) give a sense of how its business performed in the quarter ended August 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
LENNegative Net Change
earnings earnings-estimates-revisions earnings-surprise
Compared to Estimates, FedEx (FDX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for FedEx (FDX) give insight into how the company performed in the quarter ended August 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
FDXPositive Net Change
earnings earnings-estimates-revisions earnings-surprise
Scholastic (SCHL) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Scholastic (SCHL) give insight into how the company performed in the quarter ended August 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SCHLPositive Net Change
earnings earnings-estimates-revisions earnings-surprise
Hesai Group Sponsored ADR (HSAI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Hesai Group Sponsored ADR (HSAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
HSAIPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes iRadimed (IRMD) a New Buy Stock
by Zacks Equity Research
iRadimed (IRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IRMDPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Magnite (MGNI) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Magnite (MGNI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MGNIPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Advantest (ATEYY) a New Strong Buy Stock
by Zacks Equity Research
Advantest (ATEYY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ATEYYPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Sumitomo (SSUMY) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Sumitomo (SSUMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SSUMYPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PHATPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Leonardo DRS, Inc. (DRS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Leonardo DRS, Inc. (DRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DRSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
United Bankshares (UBSI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
United Bankshares (UBSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
UBSIPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Yext (YEXT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Yext (YEXT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
YEXTPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Nordea Bank (NRDBY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Nordea Bank (NRDBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NRDBYNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Costco (COST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Costco (COST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COSTNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Jabil (JBL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Jabil (JBL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JBLPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to an 182% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
EWTXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
DRUGPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Bulls Look Optimistic About Wix.com (WIX): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Wix.com (WIX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
WIXPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Think P&G (PG) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in P&G (PG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
PGNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Grab (GRAB): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Grab (GRAB) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
GRABPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Silicon Motion (SIMO): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Silicon Motion (SIMO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
SIMOPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Diebold Nixdorf, Incorporated (DBD) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Diebold Nixdorf, Incorporated (DBD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
DBDPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Roku (ROKU) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Roku (ROKU) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ROKUPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Cadence (CDNS) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Cadence (CDNS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
CDNSPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See Riot Platforms, Inc. (RIOT) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Riot Platforms, Inc. (RIOT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
RIOTNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth